Breaking News, Collaborations & Alliances

FDA Accepts Alvotech’s Biosimilar to Simponi (Golimumab) for Review

AVT05 is Alvotech’s proposed biosimilar to Simponi and Simponi Aria, which are prescribed to treat a variety of inflammatory conditions.

Author Image

By: Charlie Sternberg

Associate Editor

In 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of 5 of Alvotech’s biosimilar product candidates, including AVT05.

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to Simponi and Simponi Aria (golimumab), which are prescribed to treat a variety of inflammatory conditions. These are the first U.S. BLA filing acceptances announced for a biosimilar candidate to golimumab. The FDA review process for these applications is anticipated to be completed in the fourth quarter of 2025. “This is a significant st...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters